模式
重症监护医学
医学
治疗方式
癌症
风险分析(工程)
内科学
社会学
社会科学
作者
Tim Harris,Jonathan B. Fitzgerald,Anthony J. Coyle,Ted Reiss,Karsten Sauer
出处
期刊:GEN biotechnology
[Mary Ann Liebert]
日期:2022-06-01
卷期号:1 (3): 262-270
标识
DOI:10.1089/genbio.2022.0011
摘要
The introduction and development of T cell-based therapies to treat a variety of both hematological and solid tumors have led to substantial clinical benefits in some patients. In this brief review we introduce the different T cell modalities used and some of their key features and limitations. Emerging avenues to overcome current bottlenecks are put into perspective, especially the issues of limited persistence and efficacy that make it challenging to achieve durable clinical responses in solid tumor indications.
科研通智能强力驱动
Strongly Powered by AbleSci AI